View as cardsView as table101 Projects

Towards the development of improved insect repellents

Fiscal Year Awarded:

2026

Principal Investigator:

Josefina del Marmol

V8 protease to treat S. aureus infection and atopic dermatitis

Fiscal Year Awarded:

2026

Principal Investigator:

Isaac Chiu

Developing a biomarker of homologous recombination deficiency for enhanced PARP inhibitor efficacy across cancers

Fiscal Year Awarded:

2025

Principal Investigator:

Peter Park

Developing a synthetic biology platform for pharmaceutical biomanufacturing

Fiscal Year Awarded:

2025

Principal Investigator:

Pamela Silver

Development of allosteric activators for immunotherapy

Fiscal Year Awarded:

2025

Principal Investigator:

Stephen Blacklow

Development of small molecule inhibitors of a gut bacterial metabolic toxin

Fiscal Year Awarded:

2025

Principal Investigator:

Sloan Devlin

In vivo gene editing to treat inherited Collagen VI-related myopathies

Fiscal Year Awarded:

2025

Principal Investigator:

Amy Wagers

In vivo strategy to induce tolerance to therapeutic proteins and autoantigens

Fiscal Year Awarded:

2025

Principal Investigator:

Amy Wagers

Investigating the mode of action of a highly selective insecticide and suitability for Anopheles management

Fiscal Year Awarded:

2025

Principal Investigator:

Norbert Perrimon

Structure-based discovery of chromatin remodeling inhibitors

Fiscal Year Awarded:

2025

Principal Investigator:

Lucas Farnung

Targeting cancers by de-repressing nuclear PDC

Fiscal Year Awarded:

2025

Principal Investigator:

David Scadden

Targeting cell surface receptors for ASO delivery to bone marrow leukemia cells

Fiscal Year Awarded:

2025

Principal Investigator:

Karen Adelman

Virome screening for next generation nucleic acid delivery vectors to the lung

Fiscal Year Awarded:

2025

Principal Investigator:

George Church

Design of novel protease inhibitors to enhance immune checkpoint blockade in cancer therapy

Fiscal Year Awarded:

2024

Principal Investigator:

Mark Namchuk

Development of a synthetic promoter pipeline for safe and efficient gene therapy

Fiscal Year Awarded:

2024

Principal Investigator:

George Church

Development of novel AAV-mediated in vivo gene editing approaches to treat inherited collagen VI-related myopathies

Fiscal Year Awarded:

2024

Principal Investigator:

Amy Wagers

Functional antibody screening with micro-capsules - proof of concept with anti-EGFR

Fiscal Year Awarded:

2024

Principal Investigator:

Allon Klein

Gene editing to treat hereditary deafness

Fiscal Year Awarded:

2024

Principal Investigator:

David Corey

Identification of small molecule binders of the novel cancer immunotherapy target Bird33

Fiscal Year Awarded:

2024

Principal Investigator:

Arlene Sharpe

Multimodal imaging and machine learning for diagnosis and patient stratification with predictive biomarkers

Fiscal Year Awarded:

2024

Principal Investigator:

Peter Sorger